These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
227 related articles for article (PubMed ID: 30179619)
1. Role of Stereotactic Body Radiation Therapy for the Management of Oligometastatic Renal Cell Carcinoma. Franzese C; Franceschini D; Di Brina L; D'Agostino GR; Navarria P; Comito T; Mancosu P; Tomatis S; Scorsetti M J Urol; 2019 Jan; 201(1):70-76. PubMed ID: 30179619 [TBL] [Abstract][Full Text] [Related]
2. Role of Stereotactic Body Radiation Therapy for the Management of Oligometastatic Renal Cell Carcinoma. Franzese C; Franceschini D; Di Brina L; DʼAgostino GR; Navarria P; Comito T; Mancosu P; Tomatis S; Scorsetti M J Urol; 2019 Jan; 201(1):70-75. PubMed ID: 30577391 [TBL] [Abstract][Full Text] [Related]
3. Stereotactic ablative radiation therapy for oligometastatic renal cell carcinoma (SABR ORCA): a meta-analysis of 28 studies. Zaorsky NG; Lehrer EJ; Kothari G; Louie AV; Siva S Eur Urol Oncol; 2019 Sep; 2(5):515-523. PubMed ID: 31302061 [TBL] [Abstract][Full Text] [Related]
4. Oligo metastatic renal cell carcinoma: stereotactic body radiation therapy, if, when and how? Marvaso G; Corrao G; Oneta O; Pepa M; Zaffaroni M; Corso F; Gandini S; Cecconi A; Zerini D; Mazzola GC; Augugliaro M; Cossu Rocca M; Verri E; Cattani F; La Fauci F; Bergamaschi L; Luzzago S; Mistretta AF; Musi G; Nolè F; De Cobelli O; Orecchia R; Jereczek-Fossa BA Clin Transl Oncol; 2021 Aug; 23(8):1717-1726. PubMed ID: 33687659 [TBL] [Abstract][Full Text] [Related]
5. Stereotactic Ablative Radiation Therapy (SAbR) Used to Defer Systemic Therapy in Oligometastatic Renal Cell Cancer. Zhang Y; Schoenhals J; Christie A; Mohamad O; Wang C; Bowman I; Singla N; Hammers H; Courtney K; Bagrodia A; Margulis V; Desai N; Garant A; Choy H; Timmerman R; Brugarolas J; Hannan R Int J Radiat Oncol Biol Phys; 2019 Oct; 105(2):367-375. PubMed ID: 31377159 [TBL] [Abstract][Full Text] [Related]
6. Factors affecting survival in 37 consecutive patients undergoing de novo stereotactic radiosurgery for contiguous sites of vertebral body metastasis from renal cell carcinoma. Sellin JN; Reichardt W; Bishop AJ; Suki D; Rhines LD; Settle SH; Brown PD; Li J; Rao G; Chang EL; Tatsui CE J Neurosurg Spine; 2015 Jan; 22(1):52-9. PubMed ID: 25360530 [TBL] [Abstract][Full Text] [Related]
7. Stereotactic radiosurgery for intraventricular brain metastases. Farnia B; Voong KR; Brown PD; Allen PK; Guha-Thakurta N; Prabhu SS; Rao G; Wang Q; Zhao Z; Mahajan A J Neurosurg; 2014 Dec; 121 Suppl():26-34. PubMed ID: 25434934 [TBL] [Abstract][Full Text] [Related]
8. Radiosurgery in patients with renal cell carcinoma metastasis to the brain: long-term outcomes and prognostic factors influencing survival and local tumor control. Sheehan JP; Sun MH; Kondziolka D; Flickinger J; Lunsford LD J Neurosurg; 2003 Feb; 98(2):342-9. PubMed ID: 12593621 [TBL] [Abstract][Full Text] [Related]
9. The role of stereotactic body radiation therapy and its integration with systemic therapies in metastatic kidney cancer: a multicenter study on behalf of the AIRO (Italian Association of Radiotherapy and Clinical Oncology) genitourinary study group. Franzese C; Marvaso G; Francolini G; Borghetti P; Trodella LE; Sepulcri M; Matrone F; Nicosia L; Timon G; Ognibene L; Vinciguerra A; Alongi F; Bortolus R; Corti L; Ramella S; Magrini SM; Livi L; Jereczek-Fossa BA; Scorsetti M; Arcangeli S Clin Exp Metastasis; 2021 Dec; 38(6):527-537. PubMed ID: 34748125 [TBL] [Abstract][Full Text] [Related]
10. Safety and Efficacy of Stereotactic Ablative Radiation Therapy for Renal Cell Carcinoma Extracranial Metastases. Wang CJ; Christie A; Lin MH; Jung M; Weix D; Huelsmann L; Kuhn K; Meyer J; Desai N; Kim DWN; Pedrosa I; Margulis V; Cadeddu J; Sagalowsky A; Gahan J; Laine A; Xie XJ; Choy H; Brugarolas J; Timmerman R; Hannan R Int J Radiat Oncol Biol Phys; 2017 May; 98(1):91-100. PubMed ID: 28587057 [TBL] [Abstract][Full Text] [Related]
11. Stereotactic radiation therapy in the strategy of treatment of metastatic renal cell carcinoma: A study of the Getug group. Meyer E; Pasquier D; Bernadou G; Calais G; Maroun P; Bossi A; Theodore C; Albiges L; Stefan D; de Crevoisier R; Hennequin C; Lagrange JL; Grellard JM; Clarisse B; Licaj I; Habrand JL; Carrie C; Joly F Eur J Cancer; 2018 Jul; 98():38-47. PubMed ID: 29864737 [TBL] [Abstract][Full Text] [Related]
12. Calvarial and skull base metastases: expanding the clinical utility of Gamma Knife surgery. Kotecha R; Angelov L; Barnett GH; Reddy CA; Suh JH; Murphy ES; Neyman G; Chao ST J Neurosurg; 2014 Dec; 121 Suppl():91-101. PubMed ID: 25434942 [TBL] [Abstract][Full Text] [Related]
13. Clinical outcome of stereotactic radiosurgery for central nervous system metastases from renal cell carcinoma. Seastone DJ; Elson P; Garcia JA; Chao ST; Suh JH; Angelov L; Rini BI Clin Genitourin Cancer; 2014 Apr; 12(2):111-6. PubMed ID: 24331575 [TBL] [Abstract][Full Text] [Related]
14. Metastasis-directed stereotactic body radiotherapy for oligometastatic renal cell carcinoma: extent of tumor burden eradicated by radiotherapy. Liu Y; Long W; Zhang Z; Zhang Z; Mai L; Huang S; Han H; Zhou F; Dong P; He L World J Urol; 2021 Nov; 39(11):4183-4190. PubMed ID: 34043023 [TBL] [Abstract][Full Text] [Related]
15. Cyberknife for brain metastases of malignant melanoma and renal cell carcinoma. Hara W; Tran P; Li G; Su Z; Puataweepong P; Adler JR; Soltys SG; Chang SD; Gibbs IC Neurosurgery; 2009 Feb; 64(2 Suppl):A26-32. PubMed ID: 19165071 [TBL] [Abstract][Full Text] [Related]
16. Spine stereotactic body radiotherapy for renal cell cancer spinal metastases: analysis of outcomes and risk of vertebral compression fracture. Thibault I; Al-Omair A; Masucci GL; Masson-Côté L; Lochray F; Korol R; Cheng L; Xu W; Yee A; Fehlings MG; Bjarnason GA; Sahgal A J Neurosurg Spine; 2014 Nov; 21(5):711-8. PubMed ID: 25170656 [TBL] [Abstract][Full Text] [Related]
17. Gamma Knife surgery in the management of radioresistant brain metastases in high-risk patients with melanoma, renal cell carcinoma, and sarcoma. Powell JW; Chung CT; Shah HR; Canute GW; Hodge CJ; Bassano DA; Liu L; Mitchell L; Hahn SS J Neurosurg; 2008 Dec; 109 Suppl():122-8. PubMed ID: 19123898 [TBL] [Abstract][Full Text] [Related]
18. Treatment Outcome of metastatic lesions from renal cell carcinoma underGoing Extra-cranial stereotactic body radioTHERapy: The together retrospective study. Buti S; Bersanelli M; Viansone A; Leonetti A; Masini C; Ratta R; Procopio G; Maines F; Iacovelli R; Ciccarese C; Vitale MG; De Giorgi U; Mucciarini C; Maruzzo M; Prati G; Lattanzi E; Ciammella P; Bruni A; Andreani S; D'Abbiero N Cancer Treat Res Commun; 2020; 22():100161. PubMed ID: 31677494 [TBL] [Abstract][Full Text] [Related]
19. Lack of retroperitoneal lymphadenopathy predicts survival of patients with metastatic renal cell carcinoma. Vasselli JR; Yang JC; Linehan WM; White DE; Rosenberg SA; Walther MM J Urol; 2001 Jul; 166(1):68-72. PubMed ID: 11435825 [TBL] [Abstract][Full Text] [Related]
20. Stereotactic radiotherapy combined with immunotherapy or targeted therapy for metastatic renal cell carcinoma. Kroeze SGC; Fritz C; Schaule J; Siva S; Kahl KH; Sundahl N; Blanck O; Kaul D; Adebahr S; Verhoeff JJC; Skazikis G; Roeder F; Geier M; Eckert F; Guckenberger M BJU Int; 2021 Jun; 127(6):703-711. PubMed ID: 33113260 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]